Ask AI
ProCE Banner Activity

When Good Enough Isn’t: What to Do for Incomplete HBV DNA Suppression

Clinical Thought

Nucleos(t)ide analogues targeting the HBV polymerase have been the standard of care for decades, but they don’t always completely suppress HBV replication and rarely lead to functional cure. Can we do better? Read on to find out!

Released: December 16, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Aligos Therapeutics.

Aligos Therapeutics

Target Audience

This activity is intended for physicians, including hepatologists and gastroenterologists, and other healthcare professionals involved in the care of patients living with chronic hepatitis B.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate the limitations of current antiviral therapy for HBV

  • Outline the role of emerging biomarkers in evaluating disease status and treatment response for patients with HBV

  • Examine the role of emerging agents for chronic HBV suppression and their potential to improve patient outcomes

Disclosure

Primary Author

Mark Sulkowski, MD, FAASLD: consultant/advisor: AbbVie, Aligos, AstraZeneca, Bluejay, GSK, Precision Biosciences, Vir, Virion; researcher (paid to institution): Aligos, Bluejay, GSK, Griffols, Vir.